Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has issued an announcement.
IRLAB Therapeutics AB has appointed Roy Jonebrant as interim CFO, effective September 1, 2025, following the departure of Viktor Siewertz. Jonebrant brings extensive experience in financial management within the life sciences sector, which is expected to benefit IRLAB during its search for a permanent CFO. This leadership change is significant for IRLAB as it continues to advance its pipeline of Parkinson’s disease treatments.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing transformative treatments for Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research, the company is advancing several compounds, including Mesdopetam, Pirepemat, and IRL757, through various stages of clinical trials. IRLAB utilizes a proprietary systems biology-based research platform and is listed on Nasdaq Stockholm.
Average Trading Volume: 120,144
Technical Sentiment Signal: Sell
Current Market Cap: SEK260.9M
See more data about IRLAB.A stock on TipRanks’ Stock Analysis page.